Pyxis Oncology, Inc. (PYXS)

NASDAQ: PYXS · IEX Real-Time Price · USD
4.780
-0.080 (-1.65%)
At close: Feb 26, 2024, 4:00 PM
4.880
+0.100 (2.09%)
After-hours: Feb 26, 2024, 7:59 PM EST
-1.65%
Market Cap 215.41M
Revenue (ttm) n/a
Net Income (ttm) -94.29M
Shares Out 44.32M
EPS (ttm) -2.55
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 634,022
Open 4.860
Previous Close 4.860
Day's Range 4.600 - 5.100
52-Week Range 1.350 - 6.920
Beta 1.28
Analysts Strong Buy
Price Target 10.00 (+109.21%)
Earnings Date Mar 20, 2024

About PYXS

Pyxis Oncology, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targeting antibody, which is in Phase 1 clinical trial for the treatment of solid tumors, including non-small cell lung cancer (NSCLC) without driver mutations/translocations, breast cancer, endometrial cancer, thyroid cancer, kidney cancer, cholangiocarcinoma, bladder cancer, colorectal cancer, and he... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Oct 1, 2021
Employees 67
Stock Exchange NASDAQ
Ticker Symbol PYXS
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 6 analysts, the average rating for PYXS stock is "Strong Buy." The 12-month stock price forecast is $10.0, which is an increase of 109.21% from the latest price.

Price Target
$10.0
(109.21% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, Dec. 29, 2023 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company focused on developing next-generation therapeutics to target difficult-to-treat cancers, reporte...

2 months ago - GlobeNewsWire

Pyxis Oncology Announces Initiatives to Prioritize Lead ADC Program; Reports Financial Results for Third-Quarter 2023 and Provides Corporate Update

PYX-201 (a novel first-in-concept and first-in-class tumor stroma targeting antibody-drug conjugate [ADC] product candidate) Phase 1 trial progressing with fifth dose cohort at 3.6 mg/kg ; data expect...

3 months ago - GlobeNewsWire

Pyxis Oncology Announces Four Abstracts Accepted for Poster Presentation at Society for Immunotherapy of Cancer (SITC) 2023

BOSTON, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company focused on developing next-generation therapeutics to target difficult-to-treat cancers, today ...

5 months ago - GlobeNewsWire

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Pyxis Oncology, Inc. (NASDAQ: PYXS)

NEW YORK , Sept. 21, 2023 /PRNewswire/ -- Levi & Korsinsky announces that it has commenced an investigation of Pyxis Oncology, Inc. (NASDAQ: PYXS) concerning possible breaches of fiduciary duty.

5 months ago - PRNewsWire

Pyxis Oncology to Participate in Two Upcoming Investment Conferences

BOSTON, Aug. 31, 2023 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company focused on developing next-generation therapeutics to target difficult-to-treat cancers, today a...

6 months ago - GlobeNewsWire

Pyxis Oncology Successfully Completes Acquisition of Apexigen

Transaction adds a validated antibody-discovery platform, Phase 2 candidate and royalty stream Company positioned as a leader in next-generation, end-to-end Antibody-Drug Conjugate (“ADC”) creation wi...

6 months ago - GlobeNewsWire

Pyxis Oncology Reports Financial Results for Second-Quarter 2023 and Provides Corporate Update

Third dose cohort initiated in Phase 1 trial of PYX-201, Pyxis Oncology's first ADC product candidate Preliminary data from two Phase 1 trials on track for late 2023 to early 2024 Apexigen transaction...

7 months ago - GlobeNewsWire

APEXIGEN INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Apexigen, Inc. - APGN

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Apexigen, Inc. (...

7 months ago - Business Wire

Pyxis Oncology to Present at BTIG Virtual Biotechnology Conference

BOSTON, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company focused on developing next-generation therapeutics to target difficult-to-treat cancers, today a...

7 months ago - GlobeNewsWire

CancerVAX CEO Ryan Davies Discusses Biotech Entrepreneurship with Pyxis Oncology CEO Dr. Lara Sullivan

The two industry leaders focus on navigating the biotech industry and immuno-oncology research The two industry leaders focus on navigating the biotech industry and immuno-oncology research

8 months ago - GlobeNewsWire

APEXIGEN INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Apexigen, Inc. - APGN

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Apexigen, Inc. (...

9 months ago - Business Wire

Pyxis Oncology Advances PYX-106 and PYX-201 Clinical Programs

First subject dosed in Phase 1 trial of PYX-106, a fully human immunotherapy antibody candidate Second dose level initiated in Phase 1 trial of PYX-201, an antibody-drug conjugate (ADC) candidate Prel...

9 months ago - GlobeNewsWire

Pyxis Oncology to Acquire Apexigen

Pyxis Oncology positioned at forefront of Antibody-Drug Conjugate (ADC) development Commercially and clinically validated APXiMAB platform for antibody generation complements FACT ADC toolkit of linke...

9 months ago - GlobeNewsWire

Pyxis Oncology Reports Financial Results for the First Quarter 2023 and Provides Corporate Update

Orphan Drug Designation received for PYX-201 in pancreatic cancer Preliminary data from two Phase 1 trials anticipated late 2023 to early 2024 Strong balance sheet with $150.8 million in cash (includi...

10 months ago - GlobeNewsWire

Pyxis Oncology Reports Financial Results for the Fiscal Year Ended December 31, 2022, and Provides Corporate Update

Preliminary data from two Phase 1 trials anticipated late 2023 to early 2024

1 year ago - GlobeNewsWire

Pyxis Oncology Announces Dosing of First Subject in Phase 1 Trial of PYX-201, a Novel ADC for Solid Tumors

Milestone marks transition of Pyxis Oncology to a clinical-stage company

1 year ago - GlobeNewsWire

Pyxis Oncology to Participate in the Virtual 2023 SVB Securities Global Biopharma Conference

CAMBRIDGE, Mass., Feb. 13, 2023 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical stage company focused on developing next-generation therapeutics to target difficult-to-treat cancer...

1 year ago - GlobeNewsWire

Pyxis Oncology Announces FDA Clearance of Two IND Applications

FDA grants IND clearances of PYX-201, a novel antibody-drug conjugate (ADC) product candidate, and PYX-106, an immunotherapy product candidate

1 year ago - GlobeNewsWire

Pyxis Oncology Reports Financial Results for the Quarter Ended September 30, 2022 and Provides Corporate Update

Expands worldwide licensing agreement with Pfizer to obtain additional antibody-drug conjugate (ADC) platform components

1 year ago - GlobeNewsWire

Pyxis Oncology Reports Financial Results for the Second Quarter Ended June 30, 2022 and Provides Pipeline Update

• Prioritized pipeline to focus on most advanced programs while maintaining financial flexibility to pursue business development opportunities

1 year ago - GlobeNewsWire

Pyxis Oncology to Present at H.C. Wainwright Preclinical Cancer Drug Discovery Conference

CAMBRIDGE, Mass., June 28, 2022 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), an oncology company focused on developing next-generation therapeutics for difficult-to-treat cancers, today an...

1 year ago - GlobeNewsWire

Pyxis Oncology Announces Presentations at Upcoming Investor Conferences

CAMBRIDGE, Mass., May 19, 2022 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a multi-asset multi-modality company focused on developing next-generation therapeutics for difficult to treat c...

1 year ago - GlobeNewsWire

Pyxis Oncology Reports Financial Results for the Quarter Ended March 31, 2022 and Provides Business Update

CAMBRIDGE, Mass., May 13, 2022 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a multi-asset multi-modality company focused on developing next-generation therapeutics for difficult to treat c...

1 year ago - GlobeNewsWire

Pyxis Oncology to Participate in Fireside Chat at BofA Securities 2022 Healthcare Conference

CAMBRIDGE, Mass., April 27, 2022 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a multi-asset multi-modality company focused on developing next-generation therapeutics for difficult to treat...

1 year ago - GlobeNewsWire

Pyxis Oncology Announces Leadership Changes

- Ronald Herbst, Ph.D., stepping down as Chief Scientific Officer -

2 years ago - GlobeNewsWire